The efficacy of prolonging treatment with peginterferon alfa-2b and ribavirin to 72 weeks in chronic hepatitis C genotype 1 patients HCV RNA positive at week 8 but negative at week 12

Kanzo/Acta Hepatologica Japonica

Volumn 51, Issue 1, 2010, Pages 48-50

  Miyase, Shiho ^a   Ogata, Kenichirou ^a   Haraoka, Katsuki ^a   Morishita, Yuko ^a   Fujiyama, Shigetoshi ^a  

^a NTT West Kyushu Hospital   (Japan)

Author keywords

Chronic hepatitis C; Peginterferon plus ribavirin; Treatment extension to 72 weeks

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN; VIRUS RNA;

ANTIVIRAL THERAPY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; PREDICTOR VARIABLE; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; THROMBOCYTE COUNT; TREATMENT DURATION; VIROLOGY;

EID: 77149179791     PISSN: 04514203     EISSN: None     Source Type: Journal    
DOI: 10.2957/kanzo.51.48     Document Type: Article

References (5)

1. Sanchez-Tapias JM, Diago M, Escartin P, et al. Gastroenterology 2006; 131: 451-460
2. Pealman BL, Ehleben C, Saifee S. Hepatology 2007; 46: 1688-1694
3. Japanese source
4. Ghany MG, Strader DB, Thomas DL, et al. Hepatology 2009; 49: 1335-1374
5. Japanese source